Avid Bioservices Inc (CDMO)

[biopharm]

MDSC express suppressive factors such as arginase-1, reactive oxygen species, and inducible nitric oxide synthase, which have the ability to inhibit T cell proliferation and cytoxicity, induce the expansion of regulatory T cells, and block natural killer cell activation. It is increasingly recognized that MDSC alter the immune response to several cancers, and perhaps chronic viral infections, in clinically important ways.

... Follow the yellow brick road, from MDSC's to .... yes, nitric oxide:

---------------------

IV International Workshop on "Nitric oxide in cancer"

Sevilla, March 13-14 2015

Session 1: Nitric oxide, mutagenesis, carcinogenesis, tumor promotion and tumor growth

Session 2: Nitric oxide regulation of cell death pathways

Session 3: Nitric oxide: proliferation and epithelial-mesenchymal transition

Session 4: Regulation of immune response by nitric oxide

Session 5: Antitumoral activity of nitric oxide-based releasing strategies: pre-clinical studies

Session 6: Antitumoral activity of nitric oxide-based releasing strategies: clinical trials

Invited speakers

Dr. S. Moncada (University College London, London, UK)

Dr. S.P. Hussain (National Cancer Institute, Bethesda, USA)

Dr. D.A. Wink (National Cancer Institute, Bethesda, USA)

Dr. V.R. Yakovlev (Virginia Commonwealth University, Richmond, USA)

Dr. B. Bonavida (Johnson Comprehensive Cancer, University of California, Los Angeles, USA)

Dra. S. Planchette (Tumor Immunology and Immunotherapy Laboratory, Dijon, France)

Dr. G. Bauer (University Medical Center, Freiburg, Germany)

Dr. J.R. Lancaster (University of Alabama, Birmingham, USA)

Dr. T. R. Billiar (University of Pittsburgh, Pittsburg, USA)

Dr. I. Singh (Medical University of South Carolina, Charleston, USA)

Dr. B. Brüne (Goethe-University Frankfurt, Frankfurt, Germany)

Dr. Ch. Counter (Duke University Medical Center, Durham, USA)

Dr. J.A. Martínez-Ruiz (Hospital Universitario de La Princesa, Madrid, Spain)

Dr. Ch.H. Graham (Queen’s University, Canada)

Dr. K. Kashfi (Sophie Davis School of Biomedical Education, New York, USA)

Dra. M. Klink (Institute of Medical Biology, Lodz, Poland)

Dr. R. González (Department of Biochemistry and Molecular Biology, Córdoba, Spain)

Dr. J. Scicinski (Epicentrix Inc., California, USA)

Dr. A. Aparicio (A Coruña University Hospital, A Coruña, Spain)

Dra. V. Rapozzi (University of Udine, Udine, Italy)

http://www.celldeath-apoptosis.org/extensions/templates/other-meetings/beez5/nitric-oxide-seville-march-2015.html

-----------------------

This puzzle continues to expand... just like our solar system and the ICDS is based out of Iran, the same region where many followers to Peregrine have increased over the past year and I noticed Iran has been taking notice to how important MDSC's are becoming and being linked to cancer and hundreds of other autoimmune diseases...

http://www.celldeath-apoptosis.org/component/content/article/79-meetings/138-confirmed-speakers-prague.html

---------------------

My best guess is the scientific evidence is building and building and we will know soon enough why PS Targeting is the target of all targets. Other ways around it ? possibly.... but there are many Big Pharmas out there and they must not, never, ever be in a position where they have no immunotherapy pipeline and Peregrine has one ready and waiting.

They likely already have their backers though... CALICO still my #1 choice as we sit and wait for the higher ups to connect that final dot: MDSC's to PS Targeting to Peregrine and BAMM...

a boat load of posters will disappear as they will have no credibility, as they have doubted for way too long